464.25

+0.28%↑

SANES

9.507

+0.62%↑

SAF

278.9

+0.76%↑

BBVA

18.21

+1.34%↑

BNP

81.1

+0.76%↑

464.25

+0.28%↑

SANES

9.507

+0.62%↑

SAF

278.9

+0.76%↑

BBVA

18.21

+1.34%↑

BNP

81.1

+0.76%↑

464.25

+0.28%↑

SANES

9.507

+0.62%↑

SAF

278.9

+0.76%↑

BBVA

18.21

+1.34%↑

BNP

81.1

+0.76%↑

464.25

+0.28%↑

SANES

9.507

+0.62%↑

SAF

278.9

+0.76%↑

BBVA

18.21

+1.34%↑

BNP

81.1

+0.76%↑

464.25

+0.28%↑

SANES

9.507

+0.62%↑

SAF

278.9

+0.76%↑

BBVA

18.21

+1.34%↑

BNP

81.1

+0.76%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.184 5.15

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.1280000000000001

Max

1.192

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	78M
Ankstesnė atidarymo kaina	-3.97
Ankstesnė uždarymo kaina	1.184

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-30 23:15; UTC

Svarbiausios naujienos

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026-03-30 22:36; UTC

Svarbiausios naujienos

Australian Government Rules Out Boots on the Ground in the Middle East

2026-03-30 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026-03-30 21:00; UTC

Uždarbis

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026-03-30 20:15; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026-03-30 23:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026-03-30 23:36; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026-03-30 23:12; UTC

Rinkos pokalbiai

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026-03-30 22:49; UTC

Rinkos pokalbiai

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026-03-30 22:44; UTC

Rinkos pokalbiai

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026-03-30 22:43; UTC

Rinkos pokalbiai

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026-03-30 22:42; UTC

Rinkos pokalbiai

South32 Should Go for Growth, Says New Bull -- Market Talk

2026-03-30 22:18; UTC

Rinkos pokalbiai

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026-03-30 22:05; UTC

Rinkos pokalbiai

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026-03-30 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026-03-30 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026-03-30 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026-03-30 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026-03-30 21:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 21:25; UTC

Rinkos pokalbiai

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026-03-30 21:03; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026-03-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-30 20:09; UTC

Uždarbis

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026-03-30 20:00; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.